Core Viewpoint - The announcement details the release of a portion of shares held by a major shareholder, Zhao Minh Hai, which does not impact the company's operations or governance structure [1][2]. Group 1: Shareholder Information - Zhao Minh Hai, a shareholder holding over 5% of the company, owns 26,250,000 shares, representing 17.72% of the total share capital [1]. - The number of shares released from freezing is 15,608,364, which accounts for 59.46% of Zhao Minh Hai's total holdings [1]. - After the release, Zhao Minh Hai still has 10,000,000 shares under judicial freeze [1]. Group 2: Impact on the Company - The release of shares does not affect the company's production, control, ownership structure, or governance [2].

Group 1 - The board of directors of Jiangxi Ganyue Expressway Co., Ltd. held its 17th meeting of the 9th session on February 11, 2026, via remote voting, with all 9 eligible directors participating and casting valid votes [1][2]. - The board approved the proposal to appoint Ms. Li Shikun as the Chief Financial Officer, with her term lasting until the end of the current board's tenure [1]. - The meeting's voting results showed unanimous support, with 9 votes in favor and no votes against or abstentions [2]. Group 2 - Ms. Li Shikun, born in 1987, holds a master's degree in management and is a senior accountant. She currently serves as a member of the company's party committee and Chief Financial Officer [4]. - Ms. Li has previously held positions at Jiangxi Provincial Highway Investment Group and Jiangxi Transportation Investment Group, where she was involved in financial management and financing [4].

证券代码：600309 证券简称：万华化学 公告编号：临2026-07号 万华化学集团股份有限公司关于 ■ 上述人员确认，本次股票交易均遵守有关法律法规和监管要求，并承诺上述所购股票自买入之日起六个 月内不再卖出。 高级管理人员买入公司股票的公告 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 万华化学集团股份有限公司 万华化学集团股份有限公司（以下简称"公司"）于2026年2月11日收到公司董事、常务副总裁华卫琦先 生通知，华卫琦先生基于看好公司未来发展，于2026年2月11日以自有资金通过集合竞价交易方式买入 公司A股股票，现将有关情况公告如下： 2026年2月12日 ...

重要内容提示： ● 担保对象及基本情况 证券代码：688619 证券简称：罗普特（维权） 公告编号：2026-004 罗普特科技集团股份有限公司 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 截至本公告披露日，上述被担保人不是失信被执行人。 三、担保协议的主要内容 保证人：罗普特科技集团股份有限公司 （一）担保的基本情况 为助力子公司业务发展，罗普特科技集团股份有限公司（以下简称"公司"）的全资子公司罗普特（上 海）供应链管理有限公司拟向北京银行股份有限公司上海分行申请银行授信额度1,000万元，公司为其 提供连带责任保证担保，最高担保金额为2,000万元。 （二）内部决策程序 公司分别于2025年12月25日、2026年1月15日召开第三届董事会第十二次会议和2026年第一次临时股东 会，审议通过了《关于2026年度对外担保额度预计的议案》，同意公司为合并报表范围内各级全资及控 股子公司提供最高不超过人民币3.30亿元（或等值外币，下同）的连带责任保证担保,其中罗普特（上 海）供应链管理有限 ...

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. announced that its subsidiary, Suzhou Merdia Biopharmaceutical Co., Ltd., has received inclusion of its injectable SHR-A1811 (Rocatinib) in the list of breakthrough therapies by the National Medical Products Administration (NMPA), marking the 10th indication for which it has received breakthrough therapy certification [1] Group 1: Drug Information - Drug Name: Injectable Rocatinib (SHR-A1811) [1] - Acceptance Number: CXSL2000087 [1] - Drug Type: Therapeutic biological product [1] - Registration Category: Class 1 [1] - Application Date: December 2, 2025 [1] - Proposed Indication: First-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 (ERBB2) activating mutations [1] Group 2: Approved Indications - The injectable Rocatinib was approved for domestic market launch in May 2025, indicated for adult patients with unresectable locally advanced or metastatic NSCLC who have previously received at least one systemic therapy and have HER2 (ERBB2) activating mutations [2] Group 3: Market Context - Primary lung cancer is the most common malignant tumor globally, with GLOBOCAN 2022 data indicating approximately 2.48 million new cases and 1.82 million deaths annually, making it the leading cause of cancer mortality [3] - In 2022, China reported 1.06 million new lung cancer cases, accounting for 22.0% of all malignant tumors, and 733,300 deaths, representing 28.5% of all cancer deaths [3] - NSCLC accounts for about 85% of lung cancer cases, with approximately 2%-4% of NSCLC patients experiencing HER2 mutations, which are associated with high tumor invasiveness and poor prognosis [3] - Recent advancements in antibody-drug conjugates and highly selective HER2-TKIs have provided new treatment options for patients with advanced NSCLC harboring HER2 mutations [3] Group 4: Drug Mechanism and Competition - Injectable Rocatinib binds to HER2-expressing tumor cells, inducing cell cycle arrest and apoptosis through the release of toxins in the tumor cell lysosome [4] - Competing intravenous products in the domestic market include Roche's Ado-trastuzumab emtansine, AstraZeneca and Daiichi Sankyo's Fam-trastuzumab deruxtecan, Rongchang Biopharmaceutical's Vidisichu monoclonal antibody, and Kelun-Biotech's Bodo-trastuzumab [4] - According to EvaluatePharma, the global sales of similar products are projected to reach approximately $6.557 billion by 2024 [4] - Cumulative R&D investment for injectable Rocatinib is approximately 1.7725 billion yuan (unaudited) [4]

重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ● 梁桐灿先生持有科达制造股份有限公司（以下简称"公司"、"科达制造"）股份374,456,779股，占公司 总股本的比例为19.52%，为公司第一大股东。本次部分股份质押后，梁桐灿先生累计质押股份 202,400,000股，占其所持公司股份数的54.05%，占公司总股本的10.55%。 ● 截至2026年2月10日，梁桐灿先生及其一致行动人广东宏宇集团有限公司（以下简称"宏宇集团"）持 有公司股份438,797,931股，占公司总股本的比例为22.88%，累计质押股份266,741,152股，占其所持公 司股份数的60.79%，占公司总股本的13.91%。 一、本次股份质押情况 1、本次股份质押情况 公司近日收到第一大股东梁桐灿先生的通知，获悉其将持有的公司部分股份办理了质押登记手续，具体 情况如下： ■ 注：梁桐灿先生不是公司控股股东，但为公司第一大股东；上述股份的解质以实际办理解除质押登记手 续之日为准。 2 ...

一、本次交易的实施情况 （一）标的资产交割过户 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 牡丹江恒丰纸业股份有限公司（以下简称："公司"）拟通过发行股份的方式购买四川锦丰纸业股份有限 公司100%股权（以下简称："本次交易"）。 公司于2026年1月23日收到中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同意牡丹 江恒丰纸业股份有限公司发行股份购买资产注册的批复》（证监许可[2026]95号），具体内容详见公司 于2026年1月24日披露的《牡丹江恒丰纸业股份有限公司关于发行股份购买资产暨关联交易事项获得中 国证券监督管理委员会同意注册批复的公告》（公告编号：2026-003）。 公司在收到中国证监会的注册批复后，积极推进本次交易的实施事宜。截至本公告日，本次交易涉及标 的公司100%股权的过户手续及相关工商变更登记事宜已完成，具体情况如下： 二、关于本次交易标的资产过户情况的中介机构核查意见 （一）独立财务顾问意见 本次交易的独立财务顾问中银国际证券 ...

Group 1 - The company aims to optimize its asset structure by gradually divesting non-core assets and focusing on the natural mineral water sector within the forest health industry [2] - The board of directors approved the proposal for the pre-listing public transfer of 100% equity of a subsidiary on January 16, 2026 [2] - The company has received approval from its indirect controlling shareholder, Jilin Changbai Mountain Forest Industry Group Co., Ltd., for the equity transfer [2] Group 2 - The company submitted a pre-listing application for the equity transfer to the Jilin Changchun Property Rights Exchange on February 11, 2026 [2] - The pre-listing phase is currently in the information disclosure stage, and the final listing price has not yet been determined [3] - There are uncertainties regarding the collection of potential buyers and the timeline for the formal listing [3]

Group 1 - The company and its subsidiary, Hubei Tiensheng Pharmaceutical Co., Ltd., participated in the national organized procurement for drugs whose agreements have expired, and some products are proposed to be selected for this procurement [1] - If the procurement contracts are signed and implemented, it will help expand the sales range of the relevant products, increase market share, and enhance brand influence [1] Group 2 - The announcement was made on February 11, 2026, by the board of directors of Tiensheng Pharmaceutical Group Co., Ltd. [2]

Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of Ketoprofen Gel Patch, which is intended for pain relief [1] - The product is classified as a Class 3 chemical drug and is indicated for conditions such as osteoarthritis, shoulder periarthritis, tendonitis, and muscle pain [1] - The Ketoprofen Gel Patch contains 30mg of Ketoprofen per 10g of gel and is administered topically, with a recommended dosage of one patch twice daily [1] Group 2 - Sales of Ketoprofen Gel Patch in China's major markets are projected to be approximately 49.58 million yuan in 2024 and about 76.44 million yuan in the first half of 2025 [2] - The approval for clinical trials is expected to enhance the company's product pipeline in the orthopedic chronic disease sector, potentially improving its strategic goals and core competitiveness [3] - The company acknowledges the long development cycle and high investment associated with drug research, which may introduce uncertainties regarding the approval and market performance of the product [3]